(Q37517954)

20 August 2017

1 reference

title

Recent advances of dendritic cells (DCs)-based immunotherapy for malignant gliomas (English)

1 reference

20 August 2017

1 reference

1 reference

Der-Yang Cho

1

1 reference

20 August 2017

Shinn-Zong Lin

2

1 reference

20 August 2017

Wen-Kuang Yang

3

1 reference

20 August 2017

Den-Mei Hsu

4

1 reference

20 August 2017

Han-Chung Lee

5

1 reference

20 August 2017

Wen-Yeun Lee

6

1 reference

20 August 2017

Shih-Ping Liu

7

1 reference

20 August 2017

publication date

13 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

18

1 reference

20 August 2017

issue

9

1 reference

20 August 2017

page(s)

977-983

1 reference

Dendritic cell-based immunotherapy for malignant gliomas

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Intratumoral LAK cell and interleukin-2 therapy of human gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Relationship of lymphocyte invasion and survival of brain tumor patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Aspirin and the induction of tolerance by dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Recent advances in immunotherapy for human glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991.

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Dendritic cell vaccination in patients with malignant gliomas: current status and future directions.

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Immunotherapy for malignant gliomas: emphasis on strategies of active specific immunotherapy using autologous dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Immunotherapeutic strategies for malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

A well adapted regulatory contrivance: regulatory T cell development and the forkhead family transcription factor Foxp3.

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Extending survival in gliomas: surgical resection or immunotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Potential identity of multi-potential cancer stem-like subpopulation after radiation of cultured brain glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Glioblastoma multiforme: pathology, natural history and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Enhancement of anti-tumor immunity specific to murine glioma by vaccination with tumor cell lysate-pulsed dendritic cells engineered to produce interleukin-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Tumor antigens in astrocytic gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Glioma-associated antigen expression in oligodendroglial neoplasms. Tenascin and epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Effective induction of antiglioma cytotoxic T cells by coadministration of interferon-beta gene vector and dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Systematic comparison of dendritic cell-based immunotherapeutic strategies for malignant gliomas: in vitro induction of cytolytic and natural killer-like T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Dendritic cell-based immunotherapy of malignant gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Cancer stem cells and brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

In Vivo Persistence of Donor Cells following Adoptive Transfer of Allogeneic Dendritic Cells in HIV-Infected Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Brain tumor survival: results from the National Cancer Data Base

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Dendritic cells pulsed with total tumor RNA for activation NK-like T cells against glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Malignant gliomas in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Transcriptional expression of survivin and its splice variants in brain tumors in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18.

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

Immunotherapy of malignant brain tumors in children and adults: from theoretical principles to clinical application

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

An experimental study of dendritic cells-mediated immunotherapy against intracranial gliomas in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3727%2F096368909X12483162196962

10.3727/096368909X12483162196962

21 January 2018

Identifiers

DOI

1 reference

20 August 2017

1 reference